Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

Scientists grow miniature human myelomas in shell-less chicken eggs to study multiple myeloma

Multiple myeloma is an incurable cancer of the bone marrow. To date, no screening systems have been available to examine the effects of new drugs in a 3D environment. Researchers on the EU project OPTATIO might now fill this gap. They succeeded in growing miniature human myelomas in shell-less chicken eggs in order to screen new marine compounds for anti-myeloma activity.

5 May 2015

Research provides insights into the ability of FL118 to overcome treatment resistance

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.

30 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.

1 Apr 2015

Iron oxide nanoparticles selectively target cell surface markers in tumor microenvironments

Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells.

30 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

Two new fluorescent dyes may help localize, resect brain tumors

Two new fluorescent dyes attracted to cancer cells may help neurosurgeons more accurately localize and completely resect brain tumors, suggests a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

2 Feb 2015

Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

A study led by the National University of Singapore found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014.

26 Jan 2015

Crown's first European symposium to focus on use of Translational Platforms in oncology drug discovery

Crown Bioscience, Inc., a leading global drug discovery and development service company, has announced its first European symposium, detailing the use of Translational Platforms including Patient-Derived Xenograft (PDX) models in oncology drug discovery and development. The conference will be held on Wednesday 11th February, at the headquarters of One Nucleus in Cambridge, UK and will welcome experts from renowned pharmaceutical companies and prominent academics working in oncology.

15 Jan 2015

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114, a selective tyrosine kinase inhibitor, is active against native and mutated forms of the BCR–ABL oncogene in Philadelphia chromosome-positive leukaemias, according to preclinical cellular and in vivo results published in Leukemia.

12 Jan 2015

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

Experimental anti-cancer drugs PF-04691502 and PD-0325901 excel against colorectal cancer models

Genes make proteins and proteins tell your body's cells what to do: one talks to the next, which talks to the next, and to the next. Like a game of telephone, researchers call these "signaling pathways". Abnormalities in these signaling pathways can cause the growth and survival of cancer cells. Commonly, mutations or rearrangements of genes in the MAPK signaling pathway create cancer's fast growth, and alterations in the PI3K signaling pathway allow cancer cells to survive into virtual immortality.

26 Nov 2014

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab may enhance the antitumour activity of erlotinib by increasing the intratumoural concentration of erlotinib in some non-small-cell lung cancers expressing high levels of vascular endothelial growth factor, Japanese researchers report.

13 Nov 2014

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms.

5 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014